Literature DB >> 21127833

Anti-CCL3 autoantibodies are not markers of type 1 diabetes when measured by a commercial ELISA method.

A G Ziegler, U Mollenhauer, P Achenbach, E Bonifacio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21127833     DOI： 10.1007/s00125-010-1976-5

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  4 in total

Review 1.  Prediction and pathogenesis in type 1 diabetes.

Authors:  Anette-G Ziegler; Gerald T Nepom
Journal:  Immunity       Date:  2010-04-23       Impact factor: 31.745

2.  Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk.

Authors:  P Achenbach; V Lampasona; U Landherr; K Koczwara; S Krause; H Grallert; C Winkler; M Pflüger; T Illig; E Bonifacio; A G Ziegler
Journal:  Diabetologia       Date:  2009-07-10       Impact factor: 10.122

3.  Selective autoantibody production against CCL3 is associated with human type 1 diabetes mellitus and serves as a novel biomarker for its diagnosis.

Authors:  Naim Shehadeh; Shirly Pollack; Gizi Wildbaum; Yaniv Zohar; Itay Shafat; Reem Makhoul; Essam Daod; Fahed Hakim; Rina Perlman; Nathan Karin
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

4.  The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes.

Authors:  Janet M Wenzlau; Kirstine Juhl; Liping Yu; Ong Moua; Suparna A Sarkar; Peter Gottlieb; Marian Rewers; George S Eisenbarth; Jan Jensen; Howard W Davidson; John C Hutton
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.